微生物群对刺激性肠综合征的产生和管理的影响:叙述性综述
Mhd Bashir Almonajjed1, Mahdi Wardeh1, Abdallah Atlagh1
1Faculty of Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, 400006 Cluj-Napoca, Romania.
Medicina (Kaunas, Lithuania)
|January 25, 2025
概括
刺激性肠综合征 (IBS) 涉及肠-大脑轴的破坏和肠道微生物群的不平衡. 研究探索微生物组向疗法,如益生菌和便微生物群移植 (FMT) 以进行个性化IBS治疗.
科学领域:
- 胃肠病学 胃肠病学
- 微生物学 微生物学
- 神经科学是一个神经科学.
背景情况:
- 刺激性肠综合征 (IBS) 是一种常见的胃肠疾病,影响全球数百万人.
- 肠道炎症综合征表现为身体症状和心理并发症,如焦虑和抑郁.
- 在IBS患者中经常观察到肠道微生物群失调,涉及肠-大脑轴.
研究的目的:
- 审查肠道微生物群,免疫系统和IBS中的大脑之间的复杂相互作用.
- 突出肠-大脑轴在IBS病变发生过程中的作用.
- 讨论当前和未来的针对肠道刺激系统的微生物群治疗方法.
主要方法:
- 关于IBS,肠道微生物群和肠-大脑轴的最新研究的文献综述.
- 对诸如益生菌,益生菌,共生菌和便微生物群移植 (FMT) 等干预措施的现有研究进行分析.
- 在IBS中检查微生物失衡,免疫反应和神经信号之间的相互作用.
主要成果:
- 肠道微生物多样性的不平衡,即失生症,是IBS患者的常见特征.
- 肠-大脑轴是调解IBS症状的关键途径.
- 针对肠道微生物群的干预措施显示出潜力,但需要进一步研究有效性.
结论:
- 有效的IBS管理需要个性化治疗策略.
- 识别可靠的基于微生物群的生物标志物对于IBS诊断和治疗至关重要.
- 完善针对微生物组的治疗方法有望改善IBS患者的治疗结果.
更多相关视频
相关概念视频
Irritable Bowel Syndrome I: Introduction
240
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
240
Irritable Bowel Syndrome III: Medical and Nursing Management
160
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
160
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
310
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
310
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
130
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
130
Drugs for Treatment of Diarrhea-Predominant IBS
142
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
142
Inflammatory Bowel Disease IV: Pharmacological Management
106
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
106


